Triple therapy shows promise for advanced liver cancer
NCT ID NCT05332821
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a triple combination treatment for advanced liver cancer that has spread. It combines a procedure called TACE (which blocks blood flow to the tumor) with immunotherapy drugs (PD-1/PD-L1 inhibitors) and targeted therapies (VEGF-TKI or bevacizumab). The goal is to improve overall survival and control cancer progression. Over 1,200 participants with advanced-stage hepatocellular carcinoma were enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PD-1/PD-L1 inhibitors (e.g., atezolizumab, pembrolizumab) and VEGF-TKI/bevacizumab (e.g., sorafenib, lenvatinib)
What this could lead to
If successful, this combination could offer a new standard treatment to extend life and control advanced liver cancer that has spread.
What could go wrong
This is a completed study, but results are not yet published. The combination may cause significant side effects, and not all patients may benefit equally.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gao-Jun Teng
Nanjing, China
-
Zheng-Gang Ren
Shanghai, China